Internal Medicine, Medical Oncology · Cape Coral, FL
NPI
1881987303
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1030 Commerce Creek Blvd
Cape Coral, FL, 33909
Phone (239) 772-3544
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.0M
338,998 services
Medicare patients, 2024
1,468
Average age 75
Drug cost, 2024
$7.8M
2,249 prescriptions
Company payments, 2025
$2,619
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Liliana Bustamante was code J9271 (injection, pembrolizumab, 1 mg), 27,200 times for 37 patients. In total Liliana Bustamante billed 338,998 services in 187 codes, and Medicare paid $7.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 27,200 | 37 | $44.56 | $1.2M |
| J1756 Injection, iron sucrose, 1 mg | Office | 24,000 | 56 | $0.18 | $4,255 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 23,800 | 17 | $0.06 | $1,318 |
| J0185 Injection, aprepitant, 1 mg | Office | 15,470 | 33 | $1.33 | $21K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 13,260 | 21 | $0.27 | $3,629 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 12,960 | 15 | $38.99 | $505K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 12,300 | 28 | $2.26 | $28K |
| J0897 Injection, denosumab, 1 mg | Office | 10,560 | 61 | $20.41 | $215K |
| J9299 Injection, nivolumab, 1 mg | Office | 8,500 | 12 | $24.65 | $209K |
| J9267 Injection, paclitaxel, 1 mg | Office | 8,233 | 17 | $0.08 | $657 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,900 | 53 | $6.36 | $50K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 5,180 | 14 | $53.28 | $276K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,830 | 92 | $0.09 | $346 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,596 | 18 | $35.73 | $128K |
| J2796 Injection, romiplostim, 10 micrograms | Office | 3,258 | 11 | $77.12 | $251K |
By year: 2022 $5.1M for 324,403 services; 2023 $6.1M for 298,129 services; 2024 $7.0M for 338,998 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,695 | 948 | $7.61 | $20K |
| 36415 Venipuncture Blood Collection | 2,237 | 907 | $8.65 | $19K |
| 81003 Clinical Chemistry | 66 | 33 | $2.20 | $145 |
| 85045 Blood Count | 31 | 30 | $3.91 | $121 |
| 85046 Blood Count | 22 | 17 | $5.46 | $120 |
Medicare prescription drug claims, 2024
In 2024, the drug Liliana Bustamante prescribed most often to Medicare patients was Letrozole, with 482 prescriptions and refills. In total Liliana Bustamante wrote 2,249 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 482 | 1,330 | 167 | $11K |
| Revlimid Lenalidomide | 110 | 110 | 19 | $1.9M |
| Hydroxyurea Generic | 90 | 244 | 32 | $2,413 |
| Ondansetron Odt Ondansetron | 85 | 89 | 65 | $3,162 |
| Brukinsa Zanubrutinib | 83 | 83 | 12 | $1.1M |
| Eliquis Apixaban | 80 | 94 | 18 | $55K |
| Dexamethasone Generic | 65 | 99 | 35 | $1,473 |
| Anastrozole Generic | 61 | 173 | 24 | $1,193 |
| Tamoxifen Citrate Generic | 59 | 158 | 26 | $1,260 |
| Prednisone Generic | 55 | 79 | 32 | $315 |
| Ibrance Palbociclib | 53 | 53 | Under 11 | $816K |
| Ondansetron Hcl Generic | 49 | 49 | 46 | $1,063 |
| Exemestane Generic | 39 | 109 | 12 | $10K |
| Levothyroxine Sodium Generic | 39 | 80 | 15 | $986 |
| Imatinib Mesylate Generic | 34 | 34 | Under 11 | $37K |
Brand drugs: - claims; generic drugs: 1,577 claims; opioid claims: 74.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Liliana Bustamante $2,619 ($2,619 in general payments such as food, travel and fees) from 36 companies. The largest payer was Pfizer Inc. with $276.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 16 | $276 |
| Astellas Pharma US Inc 4503.T | 14 | $211 |
| Merck Sharp & Dohme LLC MRK | 9 | $197 |
| GlaxoSmithKline, LLC. GSK | 9 | $188 |
| Gilead Sciences, Inc. GILD | 8 | $174 |
| Intuitive Surgical, Inc. ISRG | 1 | $124 |
| SpringWorks Therapeutics, Inc. | 1 | $120 |
| Janssen Biotech, Inc. JNJ | 6 | $102 |
| Seagen Inc. PFE | 1 | $99.99 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $84.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.